|Application ||WB, FC, ICC, E|
|Description||This gene encodes a protein containing KELCH-1 like domains, as well as a BTB/POZ domain. Kelch-like ECH-associated protein 1 interacts with NF-E2-related factor 2 in a redox-sensitive manner and the dissociation of the proteins in the cytoplasm is followed by transportation of NF-E2-related factor 2 to the nucleus. This interaction results in the expression of the catalytic subunit of gamma-glutamylcysteine synthetase. Two alternatively spliced transcript variants encoding the same isoform have been found for this gene.|
|Immunogen||Purified recombinant fragment of human KEAP1 (AA: 380-624) expressed in E. Coli.|
|Formulation||Ascitic fluid containing 0.03% sodium azide.|
|Other Names||Kelch-like ECH-associated protein 1, Cytosolic inhibitor of Nrf2, INrf2, Kelch-like protein 19, KEAP1, INRF2, KIAA0132, KLHL19|
WB~~1/500 - 1/2000
FC~~1/200 - 1/400
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||KEAP1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||INRF2, KIAA0132, KLHL19|
|Function||Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome.|
|Cellular Location||Cytoplasm. Nucleus. Note=Shuttles between cytoplasm and nucleus|
|Tissue Location||Broadly expressed, with highest levels in skeletal muscle.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1.Cell Signal. 2010 Nov;22(11):1645-54. 2.Mol Cancer Ther. 2010 Feb;9(2):336-46.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.